

Appl. No. 10/748,887

Information Disclosure Statement

CERTIFICATE OF EXPRESS MAILING

EXPRESS MAIL Mailing Label Number: EL 753209188 US

Date of Deposit February 11, 2004

I hereby certify that this correspondence, fee, and all accompanying papers, if any, are being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Francene Sawyer February 11, 2004
Francene Sawyer Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/748,887
Applicant : Jürgen Engel and Manfred Peukert
Filed : July 30, 2002
Title : USE OF LHRH ANTAGONISTS IN DOSES THAT DO NOT CAUSE
CASTRATION FOR THE T-CELL MEDIATED IMMUNITY
TC/A.U. : 1616
Examiner : TBA
Docket No. : 103832-512NP

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants bring to the attention of the Examiner the documents listed on the attached PTO/SB/08 (substitute for form 1449/PTO). Copies of the listed documents are enclosed.

The information contained in this Information Disclosure Statement was cited in the International Search Report (ISR) and the International Preliminary Examination Report (IPER). A copy of the ISR and the IPER are enclosed. Applicant respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form and returning a copy to applicant.

This Information Disclosure Statement is being filed before the mailing of a first office action on the merits under 37 C.F.R. §1.97(b), and therefore no fee is necessary. However, the Commissioner is still authorized to charge any required fees to Goodwin Procter LLP Deposit Account 06-0923.

Dated: February 11, 2004

Respectfully submitted for Applicant,

A handwritten signature in black ink, appearing to read 'Ann-Marie Koss', written over a horizontal line.

Ann-Marie Koss (Reg. No. 54,237)
GOODWIN PROCTER LLP
599 Lexington Avenue
New York, NY 10022
(212) 459-7434

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	4
-------	---	----	---

Complete if Known

Application Number	10/748,887
Filing Date	July 30, 2002
First Named Inventor	Jurgen Engel
Art Unit	1616
Examiner Name	TBA
Attorney Docket Number	103832-512-NP

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ ~ Number ⁴ ~ Kind Code ⁵ (if known)				
	4	WO 98/10781	03-19-98			
	5	WO 96/03138	02-08-96			
	6	WO 96/04927	02-22-96			
	7	WO 96/22786	08-01-96			
	8	WO 99/26630	06-03-99			
	9	WO 91/04479	04-04-91			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	3	of	4
-------	---	----	---

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Complete if Known

Application Number	10/748,887
Filing Date	July 30, 2002
First Named Inventor	Jurgen Engel
Art Unit	1616
Examiner Name	TBA
Attorney Docket Number	103832-512-NP

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	16	WO 02/30351 A2	04-18-02			
	17	WO 02/30257 A2	04-18-02			
	18	WO 02/102401 A1	12-27-02			
	19	WO 00/62657	10-26-00			
	20	WO 03/011314 A2	02-13-03			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/748,887
Filing Date	July 30, 2002
First Named Inventor	Jurgen Engel
Art Unit	1616
Examiner Name	TBA
Attorney Docket Number	103832-512-NP

Sheet 2 of 4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	10	T. REISSMANN, ET AL., The LHRH Antagonist Cetrorelix: A Review; Human Reproduction Update 2000, Vol. 6, No. 4, pp. 322-331; XP-001097713	
	11	ROBIN G. FOLDESY, ET AL., Treatment With A New LHRH Antagonist (ORF-21243) IS AS EFFECTIVE AS COMPLETE CASTRATION IN THE DUNNING PROSTATIC TUMOR MODEL; Biology of Reproduction, Vol. 34, No. Suppl. 1, 1986, pg. 122; XP008020204	
	12	F. DEBRUYNE, ET AL., Albarelux Depot, A Pure GnRH Antagonist, Compared to LHRH Agonist in Patients with Prostate Cancer; European Urology, S. Karger Ag., Basel, CH, Vol. 37, No. Suppl. 2, 2000, pg. 128; XP001024927	
	13	K. ERB, ET AL., Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men - a first-dose-in-humans study; Clinical Pharmacology & Therapeutics, Vol. 67, no. 6, June 2000, pp. 660-669; XP008020354	
	14	S. FURUYA, ET AL., Preventives/remedies for Alzheimer's disease" & WO 01 78780 A (Takeda Chem Ind Ltd), Abstract; Database WPI; Week 200219, October 30, 2001, Derwent Publications Ltd., London, GB; AN 2002-011076; XP-002249847	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet	4	of	4	Application Number	10/748,887
				Filing Date	July 30, 3002
				First Named Inventor	Jurgen Engel
				Art Unit	1616
				Examiner Name	TBA
				Attorney Docket Number	103832-512-NP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	21	PCT International Search Report	
	22	DAVID R. MANN, ET AL., Effect of Neonatal Treatment with a GnRH Antagonist on Development of the Cell-Mediated Immune Response in Marmosets; American Journal of Reproductive Immunology, AJRI, 1999; 42:175-186; XP-002963846	
	23	Norwood jumps on partner's T Cel drug find; Reuter News Service; Monday March 5, 12:13 p.m.; (c) Reuters Limited 2001 http://au.dailynews.yahoo.com/finance/...utersfinance/983754780-12785871301.html)	
	24	Norwood Abbey announces new immune system stimulator; ; March 5, 2001; News & Views, (http://www.egoli.com.au/newsandviews/archives/13189.html)	
	25	Norwood Abbey receives clinical trial go-ahead; May 3, 2001; News & Views, (http://www.egoli.com.au/newsandviews/archives/14258.html)	
	26	LOU CARUANA, Breakthrough in AIDS treatment, March 6, 2001; news.com.au, (http://news.com.au/common/printpage/0,6093,1774063,00.html)	
	27	TANYA TAYLOR, Immune test cancer hope, March 6, 2001, Herald Sun, (c) 2001 Herald and weekly Times, (http://www.heraldsun.news.com.au/printpage/0,5481,1774810,00.html)	
	28	Wiederaufbau des Immunsystems; Australische Forscher haben neue Methode entdeckt; News, LifeScience.de [Restoration of Immune System, Australian Researchers Discover New Method; (English translation attached)]	
	29	PCT Notification of Transmittal of The International Preliminary Examination Report	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.